Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) ...

My life first got off track when I tried to get on my elementary school’s basketball team. In my small town in eastern Iowa, ...